Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2027

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Combination Product:t: SIRT-Y90 +HAIC+Atezolizumab + Bevacizumab

"Single or two-staged delivery of SIRT-Y90 (4 to 6 weeks), followed by 1200mg atezolizumab + 15mg/kg bevacizumab administered by IV at every 3 weeks for 18 months.~HAIC:administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries every 3 weeks."

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER